← Back to Clinical Trials
Recruiting NCT07653347

NCT07653347 Infant RSV Immunity Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07653347
Status Recruiting
Phase
Sponsor University of British Columbia
Condition Respiratory Synctial Virus
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2026-01-15
Primary Completion 2027-06-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 6 Months
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2026-01-15 with a primary completion date of 2027-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\<4 months) versus late (\>6-9 months) in infancy.

Eligibility Criteria

Inclusion Criteria: Birthing parent/child pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital. Exclusion Criteria: Severe pregnancy-related complications or chronic medical conditions in the children making them automatically eligible to receiving RSV immunoprophylaxis in British Columbia (e.g. infants born prematurely \< 35 weeks of gestation, or with chronic medical conditions).

Contact & Investigator

Central Contact

Pascal Lavoie, MDCM PhD FRCPC

✉ plavoie@bcchr.ca

📞 604-875-2135

Frequently Asked Questions

Who can join the NCT07653347 clinical trial?

This trial is open to participants of all sexes, up to 6 Months, studying Respiratory Synctial Virus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07653347 currently recruiting?

Yes, NCT07653347 is actively recruiting participants. Contact the research team at plavoie@bcchr.ca for enrollment information.

Where is the NCT07653347 trial being conducted?

This trial is being conducted at Vancouver, Canada.

Who is sponsoring the NCT07653347 clinical trial?

NCT07653347 is sponsored by University of British Columbia. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology